News | Reading Time 2 minutes

EXCITING CLINICAL WORK ON THE EFFECTS OF PROBIOTICS ON DEPRESSION

EXCITING CLINICAL WORK ON THE EFFECTS OF PROBIOTICS ON DEPRESSION

 

Ms. Caroline Wallace, a PhD candidate in Clinical Neuroscience at Queen’s University in Kingston, Canada, will be presenting her work and study at the upcoming meeting of the Sociedad Espanola de Microbiota, Probioticos Y Prebioticos (SEPYP) taking place in Granada, Spain, from February 12 to 14, 2020.

Ms. Wallace’s presentation “Bridging the Gap between Nutrition and Psychiatry Using Probiotics” examine the effects of probiotics supplements on symptoms of depression employing a combination of Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum Rosell®-175, developed by Lallemand Health Solutions. She will summarize the research on probiotics and depression to date, including preliminary results from a pilot clinical trial showing the effects of probiotic supplements on symptoms of depression, which has paved the way for a large-scale on-going clinical study (for other use than food/dietary food supplements). She will examine theories for mechanisms that may be underlying these effects and discuss how this research fits into the framework of the field of nutritional psychiatry.

Depression is a complex psychiatric disorder difficult to treat using classic antidepressant medication, mainly due to inconsistent responses to treatments from one patient to another. Ms. Wallace being a member of the Canadian Biomarker Integration Network in Depression (CAN-BIND), a national program of research and learning, she is working to find newer and more efficient ways to alleviate symptoms of depression. One of these innovative solutions may reside in the brain-gut axis. Therefore, her research focus in this emerging field, is to examine the neurobiological relationship between nutrition and mental health to develop novel treatments for depression, as well as searching for biomarkers that will help predict who will respond to these treatments.

About Lallemand Inc.

Lallemand Inc. is a privately owned Canadian company expert in the development, production, and marketing of yeast and bacteria and other ingredients linked to these microorganisms or their markets.

About Lallemand Health Solutions

Lallemand Health Solutions is a vertically integrated probiotic manufacturer specializing in the research, development and manufacturing of ready-to-market and custom probiotic formulations.

 

The information contained herein is business-to-business information and is not intended for the final consumer. It is based on our research and development work and is, to the best of our knowledge, reliable. 

Lallemand Health Solutions does not assume any liability resulting from the use of its products, as conditions of use are beyond our control. The business-to-business information provided should not be used as a substitute for any form of advice. In all instances, producers and marketers should check local regulatory requirements before use as different claims may be made depending on the regulations applicable in each country.

 

CONTACT

Bérengère Feuz, Marketing Director

Lallemand Health Solutions

healthsolutions@lallemand.com / lallemandhealthsolutions.com

Published Feb 7, 2020 | Updated Jan 12, 2024